• Bloomup

  Led · Equity · Mar 2016

  Bloomup is a Marseille-based cosmetics company co-founded in 2010 by Sophie Blin and Carol Ann Lovera. It has developed product lines including “Energie Fruit” shower gels with flavors such as blackberry, wild mint, jojoba, vanilla lily, caramel, guarana or ginseng, as well as “Mon Petit Paradis” and “Dermtec Color” for the French market. The company also distributes Physicians Formula in the USA and Baby Foot in Japan. Its products are available in major retail supermarkets, drugstores and online via BloomupShop. Bloomup raised €3.5m from ACG Management and will use the funds to expand operations. The company is backed by Amundi, Paca Investment and Sofipaca and planned to reach a turnover of €5m in 2016.

• Biom'Up

  Participated · Series C · Sep 2015

  Biom'Up develops a new generation hemostatic product, HEMOBLAST TM, and markets proprietary collagen-based products including COVA TM, COVAMESH TM and MATRITM BONE. The company focuses on absorbable medical devices for use in biosurgery. Management is led by CEO Étienne Binant. Biom'Up reported turnover of more than €3m in 2014 and expected over 30% sales growth for its existing product portfolio in 2015. The company plans to use new funds to further develop HEMOBLAST TM, specifically to support its clinical study activities in Europe and North America. Operations are based in Saint-Priest, France. Biom'Up designs, develops and manufactures re-absorbable medical implants for a range of surgical applications from nerve regeneration to cardio-thoracic surgery. Its marketed products include COVA, a membrane for prevention of adhesions and controlled healing available in Europe and the US, and MATRI BONE, a bone regeneration matrix sold in Europe. The company employs 27 people, including eight engineers and three doctors. Biom'Up plans to use new funding to strengthen its sales team to accelerate domestic and export roll-out and to finance a phase III clinical trial in Europe and the US for a new product range targeting major surgery and regenerative medicine markets. It has initiated a US development strategy by filing initial 510(k) applications with the FDA and establishing a multidisciplinary scientific advisory board of opinion leaders in France and the US. Founded in 2005 and based in Lyon, France, Biom'Up is focused on advancing its clinical pipeline and commercial expansion.

• Bioaxial

  Participated · Series A · Nov 2013

  Bioaxial is a Paris-based developer of super-resolved fluorescence microscopy focused on extended imaging of live cells. Its core product is an optical microscopy module that enables super-resolution observation of living cells over time without damaging them and can be adapted as an add-on for commercial microscopes. The module was tested at the Institut Pasteur for the prior 12 months. The company intends to use proceeds from the completed €1.9m equity funding to launch this first product, expected in the second half of 2014. Founded in 2010, Bioaxial has filed four patents and acquired a fifth and currently employs five people.

• Fermentalg

  Participated · Equity · Sep 2013

  Fermentalg develops technology to breed microalgae for industrial production of molecules used in consumer and industrial products. The company’s platform targets markets including food and animal feed, specialty chemicals, health, cosmetics and biofuels. It created Prolealg, a joint venture with Sofiproteol in 2011, to produce Omega‑3 from microalgae at scale. Fermentalg plans to scale up production of molecules of interest to industrial volumes and address large, fast‑growing markets. The company is based in Libourne, France and was founded in 2009. It completed a third funding round in 2013 to support its industrial roll‑out. Fermentalg is a Libourne, France-based biotech start up focused on developing and producing microalgae for the agrifood, healthcare and energy markets. Founded by president Pierre Calleja, the company specializes in producing micro-algae by transforming waste products into sugar that serves as energy without requiring light. Its core output is strains of microalgae produced via that process. Fermentalg raised €5.3m in its second round of funding. The company intends to use the funds to increase its research capabilities and accelerate the industrialization of its microalgae strains.

• Graftys

  Participated · Equity · Jan 2011

  Graftys develops advanced bone biologics and bone void filler products, several of which are already FDA cleared. The company intends to use the new financing to complete its first pilot clinical study for a combination medical device addressing osteoporosis locally (the M.I.A.D.R.OS project). It also plans to support establishment of commercial efforts in the US market. Graftys was created in 2005 and is headquartered in Aix-en-Provence, France. The company opened a local office in Chicago in 2009 and currently has a team of 23 employees. The financing is intended to advance both clinical and commercial programs related to its bone products.

No current team members are available.